💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

BRIEF-Valeant reports new U.S. fulfillment agreements with Walgreens

Published 2015-12-15, 08:14 a/m
© Reuters.  BRIEF-Valeant reports new U.S. fulfillment agreements with Walgreens
BHC
-

Dec 15 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* Press release - Valeant announces new U.S. fulfillment agreements with
Walgreens; plans to further extend distribution to independent pharmacies
* To reduce prices by 10 percent for all dermatological,ophthalmological
products distributed through more than 8,000 Walgreens retail outlets
* Pharma- to reduce prices by 10 percent for all dermatological and
ophthalmological products distributed through Walgreens retail outlets
* Estimates price decreases across both programs expected to provide healthcare
system up to $600 million in annual savings
* To also distribute certain branded products through Walgreens at generic
prices
* Reduced pricing will apply to wholesale list prices of products and will be
phased in over next 6-9 months
* Says agreement also covers valeant's over-the-counter product portfolio
* Co, Walgreens also entered into separate agreement under which Valeant will
distribute more than 30 branded products
* Source text for Eikon ID:nCNWtTZcta
* Further company coverage VRX.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.